• 5 min read
• Published on 2 December 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Every so often, a government does something so blindingly obvious you have to wonder what took them so long. The recent UK-US pharmaceutical trade deal feels like one of those moments. For years, we’ve watched British and American drug companies hop back and forth across the Atlantic, paying hefty tolls, known as tariffs, for the privilege. It was a bit like charging a paramedic for using the motorway. Pointless, costly, and ultimately, we all paid the price.
Well, it seems a rare outbreak of common sense has occurred in the halls of power. This new agreement scraps those tariffs entirely. Let me be clear, this isn't just some minor bit of paper shuffling. This is a fundamental shift in the economics of one of the world's most important industries.
Naturally, the first in line to benefit are the big boys. I’m looking at you, GlaxoSmithKline and AstraZeneca. These British giants have been pouring money into the American market for decades, building labs and sales teams. All the while, every box of life-saving medicine they shipped was slapped with a tax, eating into their profits and making them less competitive against their American rivals.
Suddenly, that ball and chain is gone. For a company like GSK, with its vast portfolio of vaccines and medicines, this could mean a significant boost to the bottom line. The same goes for AstraZeneca, whose cutting edge cancer drugs might now find an even bigger audience in the States. To me, it validates the expensive strategy of planting a flag on both sides of the pond. For investors, it could mean healthier margins and, one hopes, healthier dividends.
Of course, this is a two way street. The deal is just as sweet for American firms like Bristol-Myers Squibb, who have been eyeing up the NHS for years. Getting innovative new treatments, particularly for complex conditions, into the UK market was always a costly affair. The tariff system made some of their more niche, expensive drugs economically unworkable over here.
Now, that barrier has been bulldozed. American biotech firms can look at the UK not as a difficult foreign outpost, but as a profitable extension of their home market. This should lead to more competition, which is usually good news, and potentially faster access to new treatments for British patients. I suppose we have to let them win sometimes.
Here’s the thing, though. If you think this story is just about saving a few quid on shipping costs, you’re missing the point. The immediate financial relief is nice, but it’s the long term picture that I find genuinely interesting. When you make it easier for the brightest minds in Britain and America to work together, good things tend to happen.
This deal greases the wheels for more than just trade. It paves the way for deeper research collaborations, joint ventures, and strategic partnerships. The real value might not come from an AstraZeneca drug becoming a bit cheaper in Ohio, but from a new venture between a British genomics specialist and an American immunotherapy pioneer. It's this complex interplay of immediate gains and future potential that makes the UK-US Pharma Trade Deal | Tariff-Free Market Access theme so intriguing to me. It's about investing in a landscape where the best ideas can flow freely, unhindered by tedious politics. This is where the lasting value could be created, long after the initial excitement has faded.
View the full Basket:UK-US Pharma Trade Deal | Tariff-Free Market Access
View the full Basket:UK-US Pharma Trade Deal | Tariff-Free Market Access
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article